Q-omics provides the consensus-scored CSN1S2AP profile across patient tissues and cancer cell-line models. CSN1S2AP expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CSN1S2AP is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, CSN1S2AP RNA expression shows 7,859 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where CSN1S2AP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSN1S2AP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSN1S2AP survival associations across molecular data types. CSN1S2AP RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSN1S2AP RNA expression–survival associations across cancer types. High CSN1S2AP expression shows unfavorable associations in UVM, ACC, KIRP, STAD and THCA, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CSN1S2AP RNA expression.
This table summarizes CSN1S2AP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CSN1S2AP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSN1S2AP shows higher tumor expression in LIHC. The LIHC box plot shows higher CSN1S2AP RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .049).
This table shows molecular features associated with CSN1S2AP in patient tissues and cancer cell lines. In patient samples, CSN1S2AP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
